Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

h therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5 percent of its net sales.
For more information please visit www.us.boehringer-ingelheim.com

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

P-LLY
DIA568014PR

This press release cont
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Lannett Company, Inc. (NYSE: ... at the Canaccord Genuity 35th Annual Growth Conference on ... the InterContinental Boston Hotel.  A webcast ... .  Listeners are encouraged to visit the web site ... the presentation to register, download and install any necessary ...
(Date:7/30/2015)... , July 30, 2015  Arena Pharmaceuticals, Inc. ... a conference call and webcast at 5:00 p.m. Eastern ... 2015, to discuss second quarter 2015 financial results and ... results after the NASDAQ Global Select Market closes that ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/30/2015)...  Cardinal Health today reported fourth-quarter fiscal year ... 20 percent, and non-GAAP diluted earnings per share ... of 20 percent. Non-GAAP operating earnings increased 33 ... operating earnings increased 44 percent to $558 million, ... percent to $0.88. Fiscal year 2015 ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33
... for first Albuferon(R) Phase 3 trial announced in December 2008; ... - Phase 3 trials of darapladib for cardiovascular disease and ... - $106 million of convertible debt repurchased ... expected to grow to $250 million; at least $150 million ...
... Broadens Power of Current Genetic Discovery Techniques -PHILADELPHIA, Feb. 26 ... contribute to a complex disease is like searching in the ... much smaller than others, often blending into the background, and ... some needles are linked to each other by fine threads, ...
Cached Medicine Technology:Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 10The Children's Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohn's Disease Drugs 2The Children's Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohn's Disease Drugs 3The Children's Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohn's Disease Drugs 4
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on ... OncLive’s editorial and marketing groups will help spread the news about the center’s ...
(Date:7/30/2015)... , ... July 30, 2015 , ... Using the latest ... and teach people more effective ways to prevent and manage major depression. , “Suicide ... fast enough, so people fall through the cracks and die needlessly everyday,” says Walker. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer ... treatment designed specifically for the elimination of excess tissue under the chin, referred ... the state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Earns National Cancer Institute Designation , The Tisch Cancer Institute (TCI) at the ... Institute (NCI)-designated cancer center. TCI joins an elite group of 69 cancer institutions ...
(Date:7/30/2015)... ... July 30, 2015 , ... Author Dr. Raul Llanos ... health in his new self-help book, “ Consciously Healing our Webs of Health, Wellbeing, ... simple message: “If we take responsibility for ourselves, we can create better realities.” His ...
Breaking Medicine News(10 mins):Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3
... Places where you ... porn site. , ... -- The Phoenix Forum is Thursday, April 8th through Saturday, the 10th at the Tempe Mission ... to improve your traffic and revenue stream in 2010 and beyond. "I can,t wait to catch ...
... ... and positioning of healthcare technology solutions. , ... (PRWEB) April 8, 2010 -- CapSite™ Consulting, ... comparisons of contracts and proposals for Healthcare IT, Imaging Equipment and Medical Device ...
... ... a period of absence. , ... (PRWEB) April 8, 2010 -- As budget-conscious companies look for creative ways to reduce employee ... has become a quickly growing trend. Billed as a progressive workplace benefit, PRtW is designed ...
... Steven ... ... Tonkinson & Associates financial planning firm, will depart April 15th to deliver shelter and clean ... tents and life-saving supplies for up to 100,000 earthquake survivors in Haiti. Around 10,000 ...
... 2010) Educating individuals about the costs of healthcare could ... the healthcare system, report policy researchers at Tufts University School ... study is the first to assess the effect of knowledge ... by individuals out of total healthcare costs) on self-reported and ...
... ... ... of April, AthletiCo Physical Therapy and Occupational Therapy celebrates National Occupational Therapy ... the premier specialists in treating upper extremity diagnoses. , , , , ,Occupational/hand ...
Cached Medicine News:Health News:Jay Servidio President Teleteria Appearances To Discuss The Porn Business This Week 2Health News:CapSite™ Provides Detailed Transparency on Healthcare Technology Purchases 2Health News:Intellicate Announces New “Phased Return to Work” (PRtW) Service 2Health News:Intellicate Announces New “Phased Return to Work” (PRtW) Service 3Health News:Miami Businessman Heads to Haiti to Deliver ShelterBoxes 2Health News:Educate individuals to prevent sky-rocketing health care costs 2Health News:AthletiCo Offers Occupational Therapy Tips for Managing Arthritis 2Health News:AthletiCo Offers Occupational Therapy Tips for Managing Arthritis 3
... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...
... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...
... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: